Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02125825 · ClinicalTrials.gov registry record
Ambulatory Parkinson's Disease Dyskinesia Monitor for Drug Therapy Titration
A clinical trial, sponsored by Great Lakes NeuroTechnologies.
- Completed
- Registry status
- 14
- Enrollment target
NCT02125825: Completed study, sponsored by Great Lakes NeuroTechnologies.
NCT02125825 is a clinical trial that has completed, run by Great Lakes NeuroTechnologies. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02125825 has completed, sponsored by Great Lakes NeuroTechnologies.
- COMPLETED
- Registry status
- 14 participants
- Enrollment target
Study Summary
The objective is to assess a compact, portable, wireless movement disorder system with continuous monitoring capabilities to detect and quantify the severity of levodopa-induced dyskinesia in Parkinson's disease.
Primary Outcome
Motor function (movement speed and magnitude measured with a motion sensor) will be collected for a period of 2 hours after taking normally prescribed dose of levodopa.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2014-07 |
| Est. Completion | 2014-12 |
What the finished NCT02125825 record still lists
NCT02125825 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 14 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02125825 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02125825 about?
NCT02125825 is a clinical study titled "Ambulatory Parkinson's Disease Dyskinesia Monitor for Drug Therapy Titration". The objective is to assess a compact, portable, wireless movement disorder system with continuous monitoring capabilities to detect and quantify the severity of levodopa-induced dyskinesia in Parkinson's disease.
What is the current status of trial NCT02125825?
This trial is currently completed. The enrollment target is 14 participants. The study started on 2014-07. Estimated completion is 2014-12.
Who is sponsoring clinical trial NCT02125825?
This trial is sponsored by Great Lakes NeuroTechnologies, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia